BioMarin Pharmaceutical Sees $2.6 Billion Sales Potential in Amicus Drugs as VOXZOGO Expansion Looms

BioMarin Pharmaceutical (NASDAQ:BMRN) expects growth from its acquired rare disease treatments, an expanded market for VOXZOGO and a pipeline that could deliver patient data in 2027, Chief Executive Officer Alexander Hardy said at the UBS Global Biopharma Conference.

Hardy said the company’s global footprint and experience diagnosing rare diseases could help it increase sales of products acquired through Amicus Therapeutics. BioMarin also is awaiting a U.S. regulatory decision on VOXZOGO for hypochondroplasia and expects clinical data next year from two experimental treatments.

Amicus Products and Integration

BioMarin estimates peak annual sales of $1.4 billion for GALAFOLD and $1.2 billion for POMBILITI and OPFOLDA, Hardy said. He attributed those projections to BioMarin’s reach and ability to invest in the products.

For GALAFOLD, which treats Fabry disease, the company sees an opportunity to increase diagnosis and treatment rates and plans launches in another 10 countries. Hardy said the number of patients treated rose 13% in the third quarter compared with the prior year, when Amicus controlled the product.

For POMBILITI and OPFOLDA, Hardy said the opportunity centers on switching patients from existing enzyme replacement therapies. Patients on therapy grew 69% in the third quarter, he said. Hardy added that the treatment was the most prescribed Pompe drug in four European countries.

Chief Financial Officer Brian Mueller said BioMarin expects to achieve $220 million in cost synergies from approximately $430 million in Amicus non-GAAP operating expenses in calendar 2025. The company expects 2028 to be the first full year of realized synergies and believes the acquired business can reach an operating margin of about 60% by the end of the decade.

Mueller said BioMarin now expects the transaction to be accretive within its first nine months, rather than in the first calendar year after closing. The company also expects to reduce leverage to 2.5 times EBITDA by the middle of next year, almost a year earlier than originally planned.

VOXZOGO Expansion

Hardy identified three drivers for continued VOXZOGO growth in 2027: its indication for infants with achondroplasia, international expansion and a potential approval for hypochondroplasia. He said the company has a U.S. Food and Drug Administration decision date at the end of May for the latter indication.

BioMarin estimates a global addressable population of about 14,000 patients with hypochondroplasia, although diagnosis remains a challenge, Hardy said. He said the company is working to raise disease awareness and identify potential patients ahead of a possible approval.

Hardy also said VOXZOGO’s hypochondroplasia data showed stronger efficacy than its achondroplasia data, with benefits including arm span as well as measures of height and growth.

Pipeline Data Ahead

BioMarin expects to report phase 2 results next year for BMN 333, a long-acting CNP treatment being compared with VOXZOGO. Hardy said three doses are being studied and that the program is designed to move directly into a head-to-head phase 3 study against VOXZOGO.

The company also expects patient data in 2027 for BMN 440, an oral treatment under development for hypophosphatasia. Hardy said its different mechanism could potentially address symptoms such as muscle pain and weakness, though its performance in patients remains to be established.

Hardy described BMN 450, a recently acquired program for Fabry disease, as a potential subcutaneous treatment for the broader patient population. GALAFOLD is limited to patients with amenable genetic variants, which he estimated at 35% to 50% of patients.

About BioMarin Pharmaceutical (NASDAQ:BMRN)

BioMarin Pharmaceutical is a biotechnology company focused on developing and commercializing medicines for people with rare genetic diseases. Its work includes research, clinical development, manufacturing and distribution of therapies for conditions that often have limited treatment options. The company’s marketed treatments address disorders including phenylketonuria, mucopolysaccharidosis, late-infantile neuronal ceroid lipofuscinosis, achondroplasia and hemophilia A. Its products include Kuvan and Palynziq for phenylketonuria, Vimizim for Morquio A syndrome, Brineura for CLN2 disease, Voxzogo for achondroplasia and Roctavian for hemophilia A. Founded in 1997 and headquartered in San Rafael, California, BioMarin serves patients and healthcare providers in the United States and international markets, including Europe.